Lung Cancer
Volume 66, Issue 3 , Pages 350-354 , December 2009

Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer

  • Kazutoshi Isobe

      Affiliations

    • Department of Respiratory Medicine, Toho University Omori Medical Center, Japan
    • ,
  • Kunihiko Kobayashi

      Affiliations

    • Department of Respiratory Medicine, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka City, Saitama, 350-1298, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 42 984 4111; fax: +81 42 984 4667.
    • ,
  • Seiji Kosaihira

      Affiliations

    • Department of 4th Internal Medicine, Nippon Medical School, Tokyo, Japan
    • ,
  • Futoshi Kurimoto

      Affiliations

    • Respiratory Section, Saitama Cancer Center, Saitama, Japan
    • ,
  • Hiroshi Sakai

      Affiliations

    • Respiratory Section, Saitama Cancer Center, Saitama, Japan
    • ,
  • Yuka Uchida

      Affiliations

    • Department of Respiratory Medicine, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka City, Saitama, 350-1298, Japan
    • ,
  • Yoshiaki Nagai

      Affiliations

    • Department of Respiratory Medicine, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka City, Saitama, 350-1298, Japan
    • ,
  • Takefumi Yamaguchi

      Affiliations

    • Department of Respiratory Medicine, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka City, Saitama, 350-1298, Japan
    • ,
  • Akihiko Miyanaga

      Affiliations

    • Division of Internal Medicine, Tsuboi Cancer Center Hospital, Fukushima, Japan
    • ,
  • Makoto Ando

      Affiliations

    • Division of Internal Medicine, Tsuboi Cancer Center Hospital, Fukushima, Japan
    • ,
  • Gaku Mori

      Affiliations

    • Division of Internal Medicine, Tsuboi Cancer Center Hospital, Fukushima, Japan
    • ,
  • Mitsunori Hino

      Affiliations

    • Division of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan
    • ,
  • Akihiko Gemma

      Affiliations

    • Department of 4th Internal Medicine, Nippon Medical School, Tokyo, Japan

Received 28 November 2008 ,Revised 25 February 2009 ,Accepted 1 March 2009.

References 

  1. Simon GR, Turrisi A. American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324S–329S
  2. Hansen HH. Management of small-cell cancer of the lung. Lancet. 1992;339:846–849
  3. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91
  4. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043
  5. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26:4261–4267
  6. Natale RB, Lara PN, Chansky K, Crowley JJ, Jett JR, Carleton JE, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). Proc Am Soc Clin Oncol. 2008;26:400s
  7. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:65–71
  8. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20:4665–4672
  9. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–1624
  10. Jassem J, Karnicka-Młodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29:1720–1722
  11. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096
  12. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  13. Kakolyris S, Mavroudis D, Tsavaris N, Souglakos J, Tsiafaki P, Kalbakis K, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 2001;12:193–197
  14. Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer. J Clin Oncol. 2003;21:1550–1555
  15. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447
  16. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448–5453
  17. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092
  18. Park SH, Cho EK, Kim Y, Kyung SY, An CH, Lee SP, et al. Salvage treatment with topotecan in patients with irintopotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol. 2008;62:1009–1014
  19. Planting AS, Splinter TA, Ardizzoni A, Estapé J, Giaccone G, Kirkpatrick A, et al. Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer Chemother Pharmacol. 1992;29:409–411
  20. Saijo N, Niitani H. Experimental and clinical effect of ACNU in Japan with emphasis on small-cell carcinoma of the lung. Cancer Chemother Pharmacol. 1980;4:165–171
  21. Wakui A. Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas. Gan To Kagaku Ryoho. 1982;9:1327–1338
  22. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995;13:1430–1435
  23. Kirschling RJ, Grill JP, Marks RS, Kugler JW, Gerstner JB, Kuross SA, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol. 1999;22:517–522
  24. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–351
  25. Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26:777–781
  26. Fujiwara K, Yamauchi H, Suzuki S, Ishikawa H, Tanaka Y, Fujiwara M, et al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol. 2001;47:22–26
  27. Ishikawa H, Fujiwara K, Suzuki S, Tanaka Y, Kohno I. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int J Clin Oncol. 2002;7:330–333
  28. Kobayashi K, Komagata H, Sakai H, Yoneda S. Nimustine hydrochloride (ACNU) plus paclitaxel (Taxol) for refractory or relapsed lung cancer. Proc Am Soc Clin Oncol. 2002;21:222b
  29. Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007;25:253–258
  30. Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer. 2004;44:121–127

PII: S0169-5002(09)00127-5

doi: 10.1016/j.lungcan.2009.03.003

Lung Cancer
Volume 66, Issue 3 , Pages 350-354 , December 2009

Article Tools

* Image Usage & Resolution